CN110579595B - Isohemolysin, preparation method thereof, biological sample treatment method and leukocyte membrane antigen detection method - Google Patents
Isohemolysin, preparation method thereof, biological sample treatment method and leukocyte membrane antigen detection method Download PDFInfo
- Publication number
- CN110579595B CN110579595B CN201910850740.7A CN201910850740A CN110579595B CN 110579595 B CN110579595 B CN 110579595B CN 201910850740 A CN201910850740 A CN 201910850740A CN 110579595 B CN110579595 B CN 110579595B
- Authority
- CN
- China
- Prior art keywords
- content
- cell
- sample
- hemolysin
- chloride
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 210000000265 leukocyte Anatomy 0.000 title claims abstract description 19
- 239000012472 biological sample Substances 0.000 title claims abstract description 17
- 238000000034 method Methods 0.000 title claims abstract description 16
- 101710181478 Envelope glycoprotein GP350 Proteins 0.000 title claims abstract description 6
- 238000002360 preparation method Methods 0.000 title abstract description 7
- 238000001514 detection method Methods 0.000 title description 9
- 210000004027 cell Anatomy 0.000 claims abstract description 55
- 108010006464 Hemolysin Proteins Proteins 0.000 claims abstract description 46
- 239000003228 hemolysin Substances 0.000 claims abstract description 46
- 239000000523 sample Substances 0.000 claims abstract description 25
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 24
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 claims abstract description 22
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical group [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims abstract description 22
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims abstract description 21
- LPXPTNMVRIOKMN-UHFFFAOYSA-M sodium nitrite Chemical group [Na+].[O-]N=O LPXPTNMVRIOKMN-UHFFFAOYSA-M 0.000 claims abstract description 18
- ZXEKIIBDNHEJCQ-UHFFFAOYSA-N isobutanol Chemical compound CC(C)CO ZXEKIIBDNHEJCQ-UHFFFAOYSA-N 0.000 claims abstract description 14
- 239000002904 solvent Substances 0.000 claims abstract description 14
- 239000006184 cosolvent Substances 0.000 claims abstract description 13
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 claims abstract description 11
- 239000001110 calcium chloride Substances 0.000 claims abstract description 11
- 229910001628 calcium chloride Inorganic materials 0.000 claims abstract description 11
- 229910001629 magnesium chloride Inorganic materials 0.000 claims abstract description 11
- 239000011780 sodium chloride Substances 0.000 claims abstract description 11
- 229910017053 inorganic salt Inorganic materials 0.000 claims abstract description 9
- 230000003647 oxidation Effects 0.000 claims abstract description 9
- 238000007254 oxidation reaction Methods 0.000 claims abstract description 9
- 235000010288 sodium nitrite Nutrition 0.000 claims abstract description 9
- WSFSSNUMVMOOMR-NJFSPNSNSA-N methanone Chemical compound O=[14CH2] WSFSSNUMVMOOMR-NJFSPNSNSA-N 0.000 claims abstract description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 7
- 229930040373 Paraformaldehyde Natural products 0.000 claims abstract description 4
- 229920002866 paraformaldehyde Polymers 0.000 claims abstract description 4
- 238000002156 mixing Methods 0.000 claims description 14
- 210000004369 blood Anatomy 0.000 claims description 11
- 239000008280 blood Substances 0.000 claims description 11
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 claims description 8
- 239000007853 buffer solution Substances 0.000 claims description 7
- 239000000243 solution Substances 0.000 claims description 7
- 210000004698 lymphocyte Anatomy 0.000 claims description 6
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical group [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 claims description 5
- 238000000684 flow cytometry Methods 0.000 claims description 5
- 210000001616 monocyte Anatomy 0.000 claims description 5
- 210000000440 neutrophil Anatomy 0.000 claims description 5
- 239000006228 supernatant Substances 0.000 claims description 5
- 239000012736 aqueous medium Substances 0.000 claims description 4
- 235000017557 sodium bicarbonate Nutrition 0.000 claims description 4
- 229910000030 sodium bicarbonate Inorganic materials 0.000 claims description 4
- 239000003146 anticoagulant agent Substances 0.000 claims description 3
- 229940127219 anticoagulant drug Drugs 0.000 claims description 3
- 238000001914 filtration Methods 0.000 claims description 3
- 239000011259 mixed solution Substances 0.000 claims description 3
- 230000001376 precipitating effect Effects 0.000 claims description 3
- 239000007850 fluorescent dye Substances 0.000 claims description 2
- 238000001215 fluorescent labelling Methods 0.000 claims description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 abstract description 18
- 210000003743 erythrocyte Anatomy 0.000 abstract description 16
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 abstract description 9
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 abstract description 9
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 abstract description 9
- MTHSVFCYNBDYFN-UHFFFAOYSA-N diethylene glycol Chemical compound OCCOCCO MTHSVFCYNBDYFN-UHFFFAOYSA-N 0.000 abstract description 9
- 108010052285 Membrane Proteins Proteins 0.000 abstract description 3
- 102000018697 Membrane Proteins Human genes 0.000 abstract description 2
- 230000004071 biological effect Effects 0.000 abstract description 2
- 230000000717 retained effect Effects 0.000 abstract 1
- 206010018910 Haemolysis Diseases 0.000 description 15
- 230000008588 hemolysis Effects 0.000 description 14
- 238000004458 analytical method Methods 0.000 description 13
- 230000000694 effects Effects 0.000 description 12
- 239000000427 antigen Substances 0.000 description 7
- 108091007433 antigens Proteins 0.000 description 7
- 102000036639 antigens Human genes 0.000 description 7
- 239000003153 chemical reaction reagent Substances 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 6
- 239000012528 membrane Substances 0.000 description 5
- 230000003204 osmotic effect Effects 0.000 description 5
- 210000000170 cell membrane Anatomy 0.000 description 4
- 239000012634 fragment Substances 0.000 description 4
- 230000036039 immunity Effects 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- 108010054147 Hemoglobins Proteins 0.000 description 3
- 102000001554 Hemoglobins Human genes 0.000 description 3
- 108010061951 Methemoglobin Proteins 0.000 description 3
- 210000001744 T-lymphocyte Anatomy 0.000 description 3
- 238000010219 correlation analysis Methods 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 230000036737 immune function Effects 0.000 description 3
- 230000002101 lytic effect Effects 0.000 description 3
- 230000001590 oxidative effect Effects 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 238000003556 assay Methods 0.000 description 2
- 230000007969 cellular immunity Effects 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 239000012535 impurity Substances 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- 238000011068 loading method Methods 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 210000005259 peripheral blood Anatomy 0.000 description 2
- 239000011886 peripheral blood Substances 0.000 description 2
- 230000035699 permeability Effects 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 230000002335 preservative effect Effects 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 230000007928 solubilization Effects 0.000 description 2
- 238000005063 solubilization Methods 0.000 description 2
- 238000001179 sorption measurement Methods 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 231100000699 Bacterial toxin Toxicity 0.000 description 1
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 230000010100 anticoagulation Effects 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 239000000688 bacterial toxin Substances 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 229910001424 calcium ion Inorganic materials 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 238000005336 cracking Methods 0.000 description 1
- 230000002559 cytogenic effect Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 239000000834 fixative Substances 0.000 description 1
- 210000003714 granulocyte Anatomy 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 239000000644 isotonic solution Substances 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 238000012417 linear regression Methods 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000002751 lymph Anatomy 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 210000001700 mitochondrial membrane Anatomy 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 238000005192 partition Methods 0.000 description 1
- 229940021222 peritoneal dialysis isotonic solution Drugs 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 238000003908 quality control method Methods 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000010206 sensitivity analysis Methods 0.000 description 1
- 239000003998 snake venom Substances 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000009897 systematic effect Effects 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
Images
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N15/00—Investigating characteristics of particles; Investigating permeability, pore-volume or surface-area of porous materials
- G01N15/10—Investigating individual particles
- G01N15/14—Optical investigation techniques, e.g. flow cytometry
- G01N15/1404—Handling flow, e.g. hydrodynamic focusing
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N15/00—Investigating characteristics of particles; Investigating permeability, pore-volume or surface-area of porous materials
- G01N15/10—Investigating individual particles
- G01N15/14—Optical investigation techniques, e.g. flow cytometry
- G01N15/1434—Optical arrangements
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/531—Production of immunochemical test materials
- G01N33/532—Production of labelled immunochemicals
- G01N33/533—Production of labelled immunochemicals with fluorescent label
Landscapes
- Health & Medical Sciences (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Urology & Nephrology (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Dispersion Chemistry (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Abstract
The isotonic hemolysin comprises an oxidation dissolving agent, a cosolvent, a cell solubilizer, a cell fixing agent, inorganic salt and water, wherein the oxidation dissolving agent is sodium nitrite, and the content of the oxidation dissolving agent is 2-20 g/L; the cosolvent is one or more of glycerol, diethylene glycol and propylene glycol, and the content is 0.3-3 mmol/L; the cell solubilizer is one or more of isobutanol, methanol and ethanol, and the content of the cell solubilizer is 0.1-1 mol/L; the cell fixing agent is one or more of paraformaldehyde, formaldehyde, ethanol and acetone, and the content is 10-40 g/L; the inorganic salt is sodium chloride, magnesium chloride and calcium chloride, and the content of the sodium chloride is 1-10g/L, the content of the magnesium chloride is 1-100mmol/L, and the content of the calcium chloride is 1-100 mmol/L. The hemolysin preparation method, the hemolysin treatment biological sample method and the method for detecting leukocyte membrane antigen by the flow cytometer are provided at the same time, each group of leukocytes after the hemolysin treatment of the sample are obviously partitioned, leukocyte membrane protein is not damaged, the original biological activity is retained, erythrocytes can be completely cracked, the result is accurate, and the performance is stable.
Description
Technical Field
The invention relates to the field of immunological cell analysis, in particular to an isoproxysin, a preparation method thereof, a method for treating a biological sample and a method for detecting a leukocyte membrane antigen.
Background
Blood cell analysis is of great value for the development of scientific research, prevention, diagnosis and treatment of disease, ranging from the initial study of cell morphology, size, number to the recent antigenic components on cell surfaces. The traditional cell immunity and nonspecific immunity detection technology can not carry out multi-parameter and high-sensitivity analysis on the size, the shape, the plasma membrane and the internal structure of a target cell from a single cell level, a flow cytometer can quickly measure, sort, store and display a series of important characteristic parameters of dispersed cells suspended in liquid in biophysical and biochemical aspects, and can sort out specified cell subsets according to preselected parameter ranges, and the traditional cell immunity and nonspecific immunity detection technology is currently applied to the fields of clinical medicine and basic medicine research such as immunology, hematology, oncology, cytogenetics, cytobiology, biochemistry and the like, such as lymphocyte and the subset analysis of cell surface molecules, intracellular cytokine analysis, leukemia immunity typing, tumor drug resistance related protein analysis, autoimmune disease related HLA antigen analysis, cross-matching type in transplantation immunity, cross-matching type analysis, cell-specific immune function analysis, cell analysis and cell analysis, Mitochondrial membrane potential, apoptosis, intracellular calcium ion concentration, neutrophil function analysis, and the like.
Because the majority of the immune function in vivo is leucocytes, and the most abundant erythrocyte in human blood, in order to reduce the influence on the analysis of target cells, the interference effect of eliminating the erythrocyte in the blood is needed, when red blood cell hemolysis is carried out, the structure and function of white blood cells are prevented from being damaged, membrane proteins on the surfaces of the white blood cells are reserved, therefore, the requirement for hemolysis is very high, most of the existing flow cytohemolysins are hypolysins, i.e., a solution below osmotic pressure, and isotonic hemolysin, which is a solution equal to osmotic pressure, it has previously been believed that erythrocytes in isotonic solutions retain their normal form (no shrinkage, no hemolysis), but some molecules can freely pass through cell membranes to cause hemolysis of red blood cells, and the hemolysis reaction is realized by changing the physical structure of the red blood cells by utilizing the osmotic pressure difference between the inside and the outside of the cells to cause the rupture of the cell membranes. Some chemicals such as drugs, bacterial toxins, snake venom, etc. bind to ferrous hemoglobin in erythrocytes and become methemoglobin, which changes the structure of erythrocytes and leads to hemolytic reactions.
The hemolysin formula and the instrument have a certain relationship, different hemolysins are used in different instruments, the effect of the same hemolysin displayed in different instruments is different, the main reason is that the leucocyte morphology after hemolysin cracking is different, and the difference of lymphocyte, monocyte and granulocyte grouping can be caused by combining the optical path design of FSC/SSC. Many hemolysins on the market at present are only suitable for a certain type of flow cytometry, and can not achieve the effect of a hemolysin general multi-type flow cytometer.
Therefore, how to develop an isoproteolysin, a preparation method thereof, a method for processing a biological sample and a method for detecting a leukocyte antigen, which can overcome the above defects, are technical problems to be solved urgently by those skilled in the art.
Disclosure of Invention
In order to solve the technical problems, the invention provides an isotonic hemolysin preparation, the hemolysin can change the structure of red blood cells without destroying the shape, structure and function of white blood cells, has high detection accuracy and less interference impurities, can replace the hemolysin of imported like products, reduces the medical cost of hospitals, and lightens the medical expenses of patients.
In order to achieve the purpose, the technical scheme of the invention is as follows:
an isotonic hemolysin comprises an oxidation dissolving agent, a cosolvent, a cell solubilizer, a cell fixing agent, inorganic salt and water, wherein the oxidation dissolving agent is sodium nitrite, the content of the oxidation dissolving agent is 2-20g/L, and the sodium nitrite can oxidize red blood cells, so that ferrous hemoglobin in blood can be changed into methemoglobin, the red blood cells can be quickly cracked with the help of the cosolvent, and the fragments are few; the cosolvent is one or more of glycerol, diethylene glycol and propylene glycol, the content of the cosolvent is 0.3-3mmol/L, the activity of water can be reduced, soluble proteins and leukocytes can be prevented from being degraded and protected, the stability is improved, and volatilization is prevented; the cell solubilizer is one or more of isobutanol, methanol and ethanol, the content of the cell solubilizer is 0.1-1mol/L, and the cell solubilizer has high adsorption and permeation capacity on the biological membrane, so that the solubilization and the permeability of the biological membrane are changed; the cell fixing agent is one or more of paraformaldehyde, formaldehyde, ethanol and acetone, the content of the cell fixing agent is 10-40g/L, and the cell fixing agent is good for most antigens, good in tissue penetrability and small in tissue shrinkage; the inorganic salt is sodium chloride, magnesium chloride and calcium chloride, the content of the sodium chloride is 1-10g/L, the content of the magnesium chloride is 1-100mmol/L, and the content of the calcium chloride is 1-100mmol/L, and the inorganic salt is used for adjusting the conductivity and osmotic pressure in the hemolysin.
Preferably, the hemolysin further contains a trace amount of a stabilizer and a preservative.
Preferably, the hemolysin also contains a pH value regulator, wherein the pH value regulator is sodium bicarbonate, and the content of the sodium bicarbonate is 0.1-1 mmol/L.
A method for preparing isohemolysin comprises the following steps:
1) sodium nitrite, sodium chloride, calcium chloride and magnesium chloride are measured according to the content and added into a water medium to be fully dissolved to obtain a mixed solution.
2) Adding formaldehyde, glycerol and isobutanol solution into the mixed buffer solution obtained in the step 1), adding an aqueous medium to 1 liter, adjusting the pH value of sodium bicarbonate to 7.4-7.6, and filtering to obtain the hemolysin.
A method for processing a biological sample by using isoproxysin comprises the steps of adding the isoproxysin into the biological sample at room temperature, and mixing for 10-15 minutes; the biological sample is anticoagulant venous whole blood; the volume ratio of the hemolysin to the biological sample is 1: 40-3: 40.
A method for detecting an antigen of a leukocyte membrane by using an isohemolysin through a flow cytometer comprises the following steps:
1) adding a fluorescence labeling antibody for detecting cell surface molecules into a sample to be detected at room temperature, uniformly mixing, and incubating for 10-15min in a dark place;
2) adding the isohemolysin, mixing, and incubating in dark for 10 min;
3) precipitating the treated sample to be detected for 5-10min at the centrifugal speed of 300-500g by using a centrifugal machine;
4) removing supernatant from the centrifuged sample, adding PBS buffer solution, mixing the sample uniformly, and detecting;
5) the sample to be detected is analyzed by a flow cytometry and is divided into a lymphocyte population, a monocyte population and a neutrophil population according to the cell volume and granularity.
Through the technical scheme, the hemolysin is one of common auxiliary analysis reagents for detecting leukocyte antigens through flow cytometry, is also a key reagent for analyzing cellular immune functions and the like, divides leukocyte populations into lymphocytes, monocytes, neutrophils and fragments through forward angle (SSC) and side angle scattering light (FSC) on a flow cytometer according to cell size and granularity, has obvious leukocyte population partition after sample treatment, less cell fragments, does not damage leukocyte membrane protein, can retain original biological activity, can completely crack the hemolysin of erythrocytes, has accurate result and stable performance, can replace the hemolysin of imported original products, achieves the domestication of imported reagents, reduces scientific research and medical cost, reduces the medical expense of patients, has high detection accuracy and less interfering impurities, and can replace the hemolysin of COULTER series products, The BD series and other mainstream analyzers have good grouping maps, high stability and easy storage. The hemolysin of the invention has a slightly inferior color compared with other hemolysins, the color is brown when the hemolysis is started, and the hemolysis can be performed without destroying the shape, structure and function of leucocyte
Drawings
In order to more clearly illustrate the embodiments of the present invention or the technical solutions in the prior art, the drawings used in the description of the embodiments or the prior art will be briefly described below, it is obvious that the drawings in the following description are only some embodiments of the present invention, and for those skilled in the art, other drawings can be obtained according to the drawings without creative efforts.
FIG. 1 is a chart showing the hemolysis effect of an isohemolysin used in an FC500 flow cytometer (I) according to the present invention;
FIG. 2 is a diagram showing the hemolysis effect of an isopinolysin disclosed in the present invention in an FC500 flow cytometer;
FIG. 3 is a chart showing the hemolysis effect of an isopinolysin disclosed in the embodiments of the present invention in an FC500 flow cytometer;
FIG. 4 is a chart (IV) showing the hemolysis effect of an isohemolysin used in an FC500 flow cytometer, according to the present invention.
Detailed Description
The technical solutions in the embodiments of the present invention will be clearly and completely described below with reference to the drawings in the embodiments of the present invention, and the test methods in the preferred embodiments without specific reference to specific conditions are generally performed according to conventional conditions, and the described embodiments are only a part of the embodiments of the present invention, but not all of the embodiments. All other embodiments, which can be derived by a person skilled in the art from the embodiments given herein without making any creative effort, shall fall within the protection scope of the present invention.
The present invention will be described in further detail with reference to examples and specific embodiments.
As shown in fig. 1, fig. 2, fig. 3 and fig. 4, an isotonic hemolysin comprises an oxidative lytic agent, a cosolvent, a cell solubilizer, a cell fixative, a PH regulator, inorganic salts and water, wherein the oxidative lytic agent is sodium nitrite, the content of the oxidative lytic agent is 2-20g/L, the sodium nitrite can oxidize red blood cells, so that ferrous hemoglobin in blood can be changed into methemoglobin, the red blood cells can be rapidly cracked with the help of the cosolvent, and the fragments are few; the cosolvent is one or more of glycerol, diethylene glycol and propylene glycol, the content of the cosolvent is 0.3-3mmol/L, the activity of water can be reduced, soluble proteins and leukocytes can be prevented from being degraded and protected, the stability is improved, and volatilization is prevented; the cell solubilizer is one or more of isobutanol, methanol and ethanol, the content of the cell solubilizer is 0.1-1mol/L, and the cell solubilizer has high adsorption and permeation capacity on the biological membrane, so that the solubilization and the permeability of the biological membrane are changed; the cell fixing agent is one or more of paraformaldehyde, formaldehyde, ethanol and acetone, the content of the cell fixing agent is 10-40g/L, and the cell fixing agent is good for most antigens, good in tissue penetrability and small in tissue shrinkage; the pH value regulator is sodium bicarbonate, and the content of the sodium bicarbonate is 0.1-1 mmol/L; the inorganic salt is sodium chloride, magnesium chloride and calcium chloride, the content of the sodium chloride is 1-10g/L, the content of the magnesium chloride is 1-100mmol/L, and the content of the calcium chloride is 1-100mmol/L, and the inorganic salt is used for adjusting the conductivity and osmotic pressure in the hemolysin. The hemolysin also contains a trace amount of stabilizer and preservative.
On the basis of the above-mentioned isopinolysin, the invention also discloses a preparation method of isopinolysin, comprising the following steps:
s1, adding sodium nitrite, sodium chloride, calcium chloride and magnesium chloride according to the content, and fully dissolving to obtain a mixed solution.
S2, adding formaldehyde, glycerol and isobutanol solution into the mixed buffer solution obtained in the step S1, adding an aqueous medium to 1 liter, adjusting the pH value to 7.4-7.6 by using sodium bicarbonate, and filtering to obtain the hemolysin.
The method for treating a biological sample with the above-described isopinolysin is as follows: adding the hemolysin into a biological sample at room temperature, and mixing for 10-15 minutes; the biological sample is anticoagulant venous whole blood; the volume ratio of the hemolysin to the biological sample is 1: 40-3: 40.
Meanwhile, the method for detecting the leukocyte membrane antigen by using the isohemolysin through a flow cytometer comprises the following steps:
s1, adding a fluorescence labeled antibody for detecting cell surface molecules into a sample to be detected at room temperature, uniformly mixing, and incubating for 10-15min in a dark place;
s2, adding the isohemolysin, mixing, and incubating for 10min in a dark place;
s3, using a centrifuge to precipitate the processed sample to be detected for 5-10min at the centrifugation speed of 300-500 g;
s4, removing supernatant from the centrifuged sample, adding PBS buffer solution, and uniformly mixing the sample to be detected;
and S5, analyzing the sample to be detected by a flow cytometer, and sequentially dividing the sample into a lymphocyte population, a monocyte population and a neutrophil population according to the cell volume and the granularity.
Subjects and reagents: peripheral blood samples of 15 healthy and sub-healthy people are anticoagulated by EDTA, heparin and sodium citrate, stored at room temperature (18-25 ℃) and detected within 8 hours. Accuracy evaluation adopts a Cytomics FC500 flow cytometer, matched reagents of the flow cytometer are a T lymph subgroup detection four-color reagent CD45-PerCP-Cy5.5/CD4-FITC/CD8-APC/CD3-PE and matched hemolysin OptiLyse C, and the precision experiment uses Immuno-Trol cells produced by Beckman Coulter company for quality control of blood and is stored at 4 ℃.
The experimental method comprises the following steps: adding 10 mu lCD45-PerCP-Cy5.5/CD4-FITC/CD8-APC/CD3-PE antibody into a flow-type sample loading tube, adding 100 mu l of blood sample specimen by a reverse sample loading method, uniformly mixing, and incubating for 10-15min at room temperature in a dark place; adding 1000 μ l of home-made hemolysin and matched hemolysin OptiLyse C respectively, shaking, mixing, and hemolysis for 10min at room temperature in dark; precipitating the treated sample to be detected for 5-10min at the centrifugal speed of 300-500g by using a centrifugal machine; and removing supernatant from the centrifuged sample, adding PBS buffer solution, fully and uniformly mixing, and finishing the detection on the machine within 1 h.
The hemolysin of the present invention has the following degree and effect:
a, appearance of the hemolysis tube: the supernatant is clear and bright, and the red blood cells are fully cracked;
b, centrifuging to obtain a tube bottom: after centrifugation at 300g for 10min, the vessels had no visible red precipitate at the bottom and little red cell debris.
c, FSC/SSC scatter plot: the cells of each series are obviously grouped, have clear limits, high cell aggregation degree and no cross (see a hemolysis effect chart).
d, cell surface labeling: there was no significant effect on the cell membrane surface CD antigen of each line (correlation analysis table).
And e, the hemolysin can be universally used for main flow cytometers such as BD series, COULTER series and the like.
Example (b):
accuracy experiment:
to determine the inaccuracy in the results, the magnitude of the systematic error was evaluated and the following experiment was performed: and (3) selecting 15 anticoagulation peripheral blood samples of healthy and sub-healthy people, respectively measuring each sample twice by using two hemolysins, recording an experimental result, and performing linear regression and correlation analysis. TABLE 1 correlation analysis of the results of the detection of T lymphocyte subpopulations percentage from autolysin and OptiLyse C hemolysin (%)
And (3) precision experiment:
to evaluate the magnitude of random errors in the measurements, the following experiments were performed: 1, repeat run in batch: using Immuno-Trol cells to control blood quality and continuously sample and detect for 10 times by two hemolysins in the same time period respectively; 2, repeat test between batches: the blood was controlled by Immuno-Trol cells and tested once with each of the two hemolysins samples at the same time each day for 10 consecutive days.
Precision results (in batch) of the assay of T lymphocyte subpopulation percentages from homemade hemolysin and OptiLyse C hemolysin
Precision results (batch to batch) of the assay of T lymphocyte subpopulation percentages from homemade hemolysin and OptiLyse C hemolysin
The foregoing is only a preferred embodiment of the present invention, and it should be noted that, for those skilled in the art, various changes and modifications can be made without departing from the inventive concept of the present invention, and these changes and modifications are all within the scope of the present invention.
Claims (4)
1. The isotonic hemolysin is characterized by comprising an oxidation dissolving agent, a cosolvent, a cell solubilizer, a cell fixing agent, inorganic salt and water, wherein the oxidation dissolving agent is sodium nitrite, and the content of the oxidation dissolving agent is 2-20 g/L; the cosolvent is glycerol, and the content of the cosolvent is 0.3-3 mol/L; the cell solubilizer is isobutanol, and the content of the cell solubilizer is 0.1-1 mol/L; the cell fixing agent is paraformaldehyde or formaldehyde, and the content of the cell fixing agent is 10-40 g/L; the inorganic salt is sodium chloride, magnesium chloride and calcium chloride, the content of the sodium chloride is 1-10g/L, the content of the magnesium chloride is 5-10 mmol/L, and the content of the calcium chloride is 5-10 mmol/L;
the isoproxysin also contains a pH value regulator, wherein the pH value regulator is sodium bicarbonate, and the content of the sodium bicarbonate is 0.1-1 mmol/L.
2. The method of preparing an isopinohemolysin of claim 1, comprising the steps of:
1) adding sodium nitrite, sodium chloride, calcium chloride and magnesium chloride into the aqueous medium according to the content, and fully dissolving to obtain a mixed solution;
2) adding formaldehyde, glycerol and isobutanol solution into the mixed buffer solution obtained in the step 1), adding an aqueous medium to 1 liter, adjusting the pH value to 7.4-7.6 by using sodium bicarbonate, and filtering to obtain the isohemolysin.
3. The method for treating a biological sample with an isophenolysin according to claim 1, wherein said isophenolysin is added to said biological sample at room temperature and mixed for 10-15 minutes; the biological sample is anticoagulant venous whole blood; the volume ratio of the isoproxysin to the biological sample is 1: 40-3: 40.
4. the method of detecting a leukocyte membrane antigen by flow cytometry of an isophtholysin of claim 1 comprising the steps of:
1) adding a fluorescence labeling antibody for detecting cell surface molecules into a sample to be detected at room temperature, uniformly mixing, and incubating for 10-15min in a dark place;
2) adding the isohemolysin, mixing, and incubating in dark for 10 min;
3) precipitating the processed sample to be detected for 5-10min at a centrifugal speed of 300-500g by using a centrifugal machine;
4) removing supernatant from the centrifuged sample, adding PBS buffer solution, mixing the sample uniformly, and detecting;
5) the sample to be detected is analyzed by a flow cytometry and is divided into a lymphocyte population, a monocyte population and a neutrophil population according to the cell volume and granularity.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910850740.7A CN110579595B (en) | 2019-09-10 | 2019-09-10 | Isohemolysin, preparation method thereof, biological sample treatment method and leukocyte membrane antigen detection method |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910850740.7A CN110579595B (en) | 2019-09-10 | 2019-09-10 | Isohemolysin, preparation method thereof, biological sample treatment method and leukocyte membrane antigen detection method |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN110579595A CN110579595A (en) | 2019-12-17 |
| CN110579595B true CN110579595B (en) | 2022-02-18 |
Family
ID=68812809
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201910850740.7A Expired - Fee Related CN110579595B (en) | 2019-09-10 | 2019-09-10 | Isohemolysin, preparation method thereof, biological sample treatment method and leukocyte membrane antigen detection method |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN110579595B (en) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111504887B (en) * | 2020-05-09 | 2023-05-09 | 苏州四正柏生物科技有限公司 | Hemolysin and preparation method thereof |
| CN111781047A (en) * | 2020-07-03 | 2020-10-16 | 四川恒健生物科技有限公司 | Hemolysin for blood analysis and preparation method and reagent thereof |
| CN113218847A (en) * | 2021-04-12 | 2021-08-06 | 武汉凯普瑞生物技术有限公司 | Hemolytic agent for flow cytometry analysis and preparation method and application method thereof |
| CN114624165B (en) * | 2022-03-10 | 2023-05-23 | 杭州翔宇医学检验实验室有限公司 | Method for measuring neutrophil CD64 in blood sample |
| CN116046491A (en) * | 2022-12-30 | 2023-05-02 | 苏州百源基因技术有限公司 | Sample processing reagent and application thereof in flow cytometry |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101988082A (en) * | 2009-07-31 | 2011-03-23 | 深圳迈瑞生物医疗电子股份有限公司 | Leukocyte classified counting reagent, kit and preparation method thereof and method of leukocyte classified counting |
| CN103698501A (en) * | 2013-12-23 | 2014-04-02 | 深圳市开立科技有限公司 | Cyanide-free hemolytic agent |
| CN109735484A (en) * | 2018-12-12 | 2019-05-10 | 重庆中元汇吉生物技术有限公司 | Cell protection agent, reagent and use of reagent |
-
2019
- 2019-09-10 CN CN201910850740.7A patent/CN110579595B/en not_active Expired - Fee Related
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101988082A (en) * | 2009-07-31 | 2011-03-23 | 深圳迈瑞生物医疗电子股份有限公司 | Leukocyte classified counting reagent, kit and preparation method thereof and method of leukocyte classified counting |
| CN103698501A (en) * | 2013-12-23 | 2014-04-02 | 深圳市开立科技有限公司 | Cyanide-free hemolytic agent |
| CN109735484A (en) * | 2018-12-12 | 2019-05-10 | 重庆中元汇吉生物技术有限公司 | Cell protection agent, reagent and use of reagent |
Non-Patent Citations (1)
| Title |
|---|
| The Reaction between Nitrite and Oxyhemoglobin;Agens Keszler et al.;《THE JOURNAL OF BIOLOGICAL CHEMISTRY》;20080411;第283卷(第15期);第9621页方案1、第9616页图1 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN110579595A (en) | 2019-12-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN110579595B (en) | Isohemolysin, preparation method thereof, biological sample treatment method and leukocyte membrane antigen detection method | |
| Wardlaw et al. | Quantitative buffy coat analysis: A new laboratory tool functioning as a screening complete blood cell count | |
| Wintrobe | Wintrobe's clinical hematology | |
| Blaxhall et al. | Routine haematological methods for use with fish blood | |
| US4751188A (en) | Method for the simultaneous quantitative determination of cells and reagent therefor | |
| Mulcahy | Blood values in the pike Esox lucius L. | |
| Lokwani | The ABC of CBC: Interpretation of complete blood count and histograms | |
| Shu et al. | Evaluation of Mindray BC‐3600 hematology analyzer in a university hospital | |
| Vučetić et al. | Flow cytometry analysis of platelet populations: usefulness for monitoringthe storage lesion in pooled buffy-coat platelet concentrates | |
| Asaduzzaman et al. | Assessment of red blood cell indices, white blood cells, platelet indices and procalcitonin of chronic kidney disease patients under hemodialysis | |
| Gajbhiye et al. | Blood Report Analysis-A Review | |
| Madkaikar et al. | Paroxysmal nocturnal haemoglobinuria: diagnostic tests, advantages, & limitations | |
| CN111713487B (en) | A kind of reagent red blood cell preservation system and preparation method thereof | |
| CN110501490B (en) | Isotonic hemolysin, preparation method thereof, method for treating biological sample and method for detecting leukocyte membrane antigen | |
| JP2002207035A (en) | Method for counting tumorigenic cell | |
| Dai et al. | Two cases of false platelet clumps flagged by the automated hematology analyzer Sysmex XE-2100 | |
| Guidi | Hematological Diagnostics | |
| Badawi et al. | Evaluation of a point‐of‐care method for screening blood donors for sickle cell status | |
| Shagana | Diagnostic cells in the peripheral blood smear | |
| Sugiyama et al. | Performance evaluation of Celltac G: a new automated hematology analyzer | |
| Çelik et al. | Novel markers in predicting Brucella sacroiliitis: The platelet large cell ratio and basal immature reticulocyte fraction | |
| Zandecki et al. | Spurious counts and spurious results on hematology analyzers: white blood cells, red blood cells, hemoglobin, red cell indices, and reticulocytes | |
| CN111781047A (en) | Hemolysin for blood analysis and preparation method and reagent thereof | |
| JPH116831A (en) | Method for detecting and measuring blood platelet including premature rete blood platelet and adoption of the same to clinic | |
| Kubiak et al. | The diagnostic pitfalls and challenges associated with basic hematological tests |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20220218 |